Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Delft – page 102

1 232 clinical trials in Delft, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Delft at a glance
1 232
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 232 trials in Delft

Open in trial search

Bladder cancer

Not recruiting

Study on Mitomycin, Capecitabine, Ipilimumab, and Nivolumab for Muscle Invasive Bladder Cancer Treatment in Patients Seeking Bladder-Sparing Options

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Metastases to central nervous system

Not recruiting

Study of SGM-101 fluorescent antibody to detect brain metastases from colorectal cancer during surgery

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Rectal cancer

Not recruiting

Study of SGM-101 Fluorescent Imaging for Detection of Early Rectal Cancer in Patients with Suspected T1 Adenocarcinoma or High-Grade Dysplasia

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Hodgkin's disease

Not recruiting

Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

HIV infection

Not recruiting

Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Abacavir Sulfate
  • Sponsor:Radboud universitair medisch centrum Stichting

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Back pain

Not recruiting

Study on Amoxicillin for Patients with Chronic Low Back Pain and Modic Type I Changes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Amoxicillin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Frontotemporal dementia

Not recruiting

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Cystic fibrosis

Not recruiting

Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor for Cystic Fibrosis in Patients Aged 12 Months and Older

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Delft

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular disease management and prevention, including studies of novel treatments for atherosclerotic cardiovascular disease and innovative therapies targeting lipoprotein reduction.

  • Lipid Management Studies
  • Cardiovascular Risk Prevention
  • Major Adverse Cardiac Events

Research exploring both established and experimental treatments to reduce cardiovascular complications and improve patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, with significant focus on prostate cancer, breast cancer, and blood cancers including chronic lymphocytic leukemia.

  • Advanced Imaging Techniques
  • Targeted Therapies
  • Treatment Combinations

Innovative approaches combining established treatments with novel therapeutic agents to enhance treatment effectiveness.

03 Women's Health

Studies addressing various aspects of women's health, including infertility treatments and management of uterine fibroids.

  • Reproductive Health
  • Gynecological Conditions
  • Quality of Life Studies

Research comparing different treatment modalities and their impact on patient outcomes and quality of life.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.